Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies.
Location: United States, California, Palo Alto
Employees: 11-50
Founded date: 2021
Investors 3
| Date | Name | Website |
| - | S32 | s32.com |
| 22.11.2023 | Two Sigma ... | twosigmave... |
| 14.02.2023 | Blue Ventu... | blueventur... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 13.12.2021 | Blockchain.com is seeking an ambitious $20 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 13.12.2021 | Blockchain.com is seeking an ambitious $20 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 12.12.2021 | Exai Bio Secures $67.5 Million Series A Financing to Advance... | Exai Bio, a next-generation liquid biopsy company, announced it has raised a $67.5 million Series A ... | aithority.... |